share_log

Canopy Growth | DEFA14A: Others

Canopy Growth | DEFA14A:其他

SEC announcement ·  02/09 23:44
牛牛AI助理已提取核心訊息
Canopy Growth Corporation reported its financial results for the third quarter of fiscal year 2024, ending December 31, 2023. The company saw a 9% year-over-year increase in Canada adult-use cannabis business-to-business net revenue and an 11% increase in Canada medical cannabis net revenue. Despite a 7% decline in consolidated net revenue year-over-year, gross margins improved significantly, with consolidated gross margins reaching 36% and Canada cannabis gross margins increasing to 28%. The company also reported a record quarter for medical sales and a 54% sequential increase in net revenue for Storz & Bickel, driven by strong sales of the new VENTY portable vaporizer. Free cash flow from continuing operations improved by 57% year-over-year, and the company reduced overall debt by $69MM during the quarter...Show More
Canopy Growth Corporation reported its financial results for the third quarter of fiscal year 2024, ending December 31, 2023. The company saw a 9% year-over-year increase in Canada adult-use cannabis business-to-business net revenue and an 11% increase in Canada medical cannabis net revenue. Despite a 7% decline in consolidated net revenue year-over-year, gross margins improved significantly, with consolidated gross margins reaching 36% and Canada cannabis gross margins increasing to 28%. The company also reported a record quarter for medical sales and a 54% sequential increase in net revenue for Storz & Bickel, driven by strong sales of the new VENTY portable vaporizer. Free cash flow from continuing operations improved by 57% year-over-year, and the company reduced overall debt by $69MM during the quarter. Canopy Growth reaffirmed its expectation to achieve positive Adjusted EBITDA in each business unit by the end of FY2024. A special shareholder meeting is scheduled for April 12, 2024, to move forward with the Canopy USA strategy. The company also announced the appointment of two new board members, Willy Kruh and Luc Mongeau, effective February 7, 2024.
Canopy Growth Corporation公佈了截至2023年12月31日的2024財年第三季度的財務業績。該公司的加拿大成人用大麻企業對企業淨收入同比增長9%,加拿大醫用大麻淨收入增長11%。儘管合併淨收入同比下降了7%,但毛利率卻顯著提高,合併毛利率達到36%,加拿大大麻毛利率增至28%。該公司還報告稱,在新款VENTY便攜式蒸發器的強勁銷售的推動下,醫療銷售創下了創紀錄的季度,Storz & Bickel的淨收入連續增長了54%。來自持續經營業務的自由現金流同比增長了57%,該公司在本季度的總債務減少了6,900萬美元。Canopy Growth重申了其預期,即在 FY2024 結束之前,每個業務部門的調整後息稅折舊攤銷前利潤將實現正數。計劃於2024年4月12日舉行特別股東大會,以推進Canopy USA的戰略。該公司還宣佈任命兩名新的董事會成員,威利·克魯和盧克·蒙戈,自2024年2月7日起生效。
Canopy Growth Corporation公佈了截至2023年12月31日的2024財年第三季度的財務業績。該公司的加拿大成人用大麻企業對企業淨收入同比增長9%,加拿大醫用大麻淨收入增長11%。儘管合併淨收入同比下降了7%,但毛利率卻顯著提高,合併毛利率達到36%,加拿大大麻毛利率增至28%。該公司還報告稱,在新款VENTY便攜式蒸發器的強勁銷售的推動下,醫療銷售創下了創紀錄的季度,Storz & Bickel的淨收入連續增長了54%。來自持續經營業務的自由現金流同比增長了57%,該公司在本季度的總債務減少了6,900萬美元。Canopy Growth重申了其預期,即在 FY2024 結束之前,每個業務部門的調整後息稅折舊攤銷前利潤將實現正數。計劃於2024年4月12日舉行特別股東大會,以推進Canopy USA的戰略。該公司還宣佈任命兩名新的董事會成員,威利·克魯和盧克·蒙戈,自2024年2月7日起生效。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。